The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of decline in the category.
An examination of the range of different trends and forces that are acting on the pharmaceutical sector – some of them well established, others only just emerging.
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio